Royal Biologics Launches MAXX-BMC Bone Marrow Aspirate Concentration System

By Julie A. Vetalice

Royal Biologics Launches MAXX-BMC Bone Marrow Aspirate Concentration System

Royal Biologics announced FDA 510(k) clearance and U.S. launch of MAXX™-BMC. MAXX-BMC is a bone marrow aspirate concentration system that provides users with an optimal sample of concentrated bone marrow aspirate from a patient at point of care. Royal's "Lead Screw" technology in their Maxx concentration device allows users to develop a customized sample for use during orthopedic and sports medicine surgical procedures. MAXX-BMC is the latest addition featured in Royal Biologics' portfolio of Advanced Cellular Technologies & Enhanced Autologous Healing systems.

Lead Screw technology allows clinicians to pinpoint precise and accurate areas of the "Buffy Coat" fraction (growth factor layer) of bone marrow aspirate in a matter of seconds post-concentration. Maxx-BMC provides up to two concentration cycles in eight minutes.

Royal Biologics' Enhanced Autologous Healing and Advanced Cellular Portfolio now comprises five systems: FIBRINET™ (Platelet Rich Fibrin Matrix), OSTEO™-SPIN, MAXX™-Cell (bone marrow harvester), MAXX™-PRP (Platelet Rich Plasma) and MAXX-BMC (Bone Marrow Aspirate Concentrate).

Source: Royal Biologics

Product Labels: PRP/Cell-Based/Osteoinductive Materials

Tags: Product Launch